X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with THOMAS COOK INDIA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs THOMAS COOK INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

THOMAS COOK INDIA 
   Change

Thomas Cook India (TCIL) offers a broad spectrum of leisure travel related services such as package tours, currency exchange and travel insurance as well as hotel and flight reservations. TCIL has been present in India for 128 years. In 2006, the com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES THOMAS COOK INDIA INDOCO REMEDIES/
THOMAS COOK INDIA
 
P/E (TTM) x 32.6 879.5 3.7% View Chart
P/BV x 3.9 4.2 93.0% View Chart
Dividend Yield % 0.6 0.2 382.6%  

Financials

 INDOCO REMEDIES   THOMAS COOK INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
THOMAS COOK INDIA
Mar-17
INDOCO REMEDIES/
THOMAS COOK INDIA
5-Yr Chart
Click to enlarge
High Rs360238 151.3%   
Low Rs249166 150.4%   
Sales per share (Unadj.) Rs119.0234.2 50.8%  
Earnings per share (Unadj.) Rs8.42.1 394.9%  
Cash flow per share (Unadj.) Rs15.24.4 344.2%  
Dividends per share (Unadj.) Rs1.600.38 421.1%  
Dividend yield (eoy) %0.50.2 279.0%  
Book value per share (Unadj.) Rs70.741.5 170.5%  
Shares outstanding (eoy) m92.15366.76 25.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.9 297.0%   
Avg P/E ratio x36.495.3 38.2%  
P/CF ratio (eoy) x20.045.6 43.9%  
Price / Book Value ratio x4.34.9 88.5%  
Dividend payout %19.117.9 106.6%   
Avg Mkt Cap Rs m28,08374,049 37.9%   
No. of employees `0006.02.3 264.2%   
Total wages/salary Rs m2,16740,539 5.3%   
Avg. sales/employee Rs Th1,817.037,584.2 4.8%   
Avg. wages/employee Rs Th359.017,741.3 2.0%   
Avg. net profit/employee Rs Th127.7339.9 37.6%   
INCOME DATA
Net Sales Rs m10,96885,880 12.8%  
Other income Rs m40750 5.3%   
Total revenues Rs m11,00786,630 12.7%   
Gross profit Rs m1,5653,319 47.1%  
Depreciation Rs m633846 74.8%   
Interest Rs m621,309 4.7%   
Profit before tax Rs m9091,914 47.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1391,138 12.2%   
Profit after tax Rs m771777 99.2%  
Gross profit margin %14.33.9 369.2%  
Effective tax rate %15.359.5 25.6%   
Net profit margin %7.00.9 777.0%  
BALANCE SHEET DATA
Current assets Rs m5,72534,451 16.6%   
Current liabilities Rs m5,45432,401 16.8%   
Net working cap to sales %2.52.4 103.4%  
Current ratio x1.01.1 98.7%  
Inventory Days Days620 19,440.5%  
Debtors Days Days7240 179.9%  
Net fixed assets Rs m5,30722,384 23.7%   
Share capital Rs m184367 50.2%   
"Free" reserves Rs m6,33114,840 42.7%   
Net worth Rs m6,51615,206 42.8%   
Long term debt Rs m1,3237,376 17.9%   
Total assets Rs m11,97064,131 18.7%  
Interest coverage x15.62.5 635.4%   
Debt to equity ratio x0.20.5 41.9%  
Sales to assets ratio x0.91.3 68.4%   
Return on assets %7.03.3 213.9%  
Return on equity %11.85.1 231.6%  
Return on capital %12.414.3 86.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,507333 1,352.6%   
Fx outflow Rs m1,141125 910.2%   
Net fx Rs m3,366208 1,619.6%   
CASH FLOW
From Operations Rs m8862,855 31.0%  
From Investments Rs m-1,706-2,665 64.0%  
From Financial Activity Rs m1,3161,551 84.8%  
Net Cashflow Rs m4971,779 27.9%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 0.2 6,250.0%  
FIIs % 6.0 12.4 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 12.4 180.6%  
Shareholders   12,805 34,019 37.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   INDIABULLS FIN. SER.  NALWA SONS INV  CREST VENTURES  TIMKEN INDIA  RELIGARE ENT.  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - MOTILAL OSWAL COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS